Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD

Aili L. Lazaar, Bruce E. Miller, Maggie Tabberer, John Yonchuk, Nancy Leidy, Claire Ambery, Jackie Bloomer, Henrik Watz, Ruth Tal-Singer

Source: Eur Respir J, 52 (4) 1801020; 10.1183/13993003.01020-2018
Journal Issue: October
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Aili L. Lazaar, Bruce E. Miller, Maggie Tabberer, John Yonchuk, Nancy Leidy, Claire Ambery, Jackie Bloomer, Henrik Watz, Ruth Tal-Singer. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD. Eur Respir J, 52 (4) 1801020; 10.1183/13993003.01020-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effects of successful treatment of cough on health status
Source: Annual Congress 2003 - Cough and sleep disorders
Year: 2003


Effects of CXCR2 antagonists on neutrophil chemotaxis from COPD patients
Source: Annual Congress 2010 - Airway cells as targets for anti-inflammatory drugs
Year: 2010

Effects of nutritional status on dyspnea in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 253s
Year: 2002

Effect of long-acting muscarinic antagonist (LAMA) on 24-hour physical behaviours in COPD
Source: Virtual Congress 2020 – Reviews and novel insights into pulmonary rehabilitation
Year: 2020


Effects of integrated care on lung function and health status in COPD patients
Source: Annual Congress 2004 - Burden of obstructive lung diseases: costs, mortality and life impairment
Year: 2004


Effect of leukotriene receptor antagonist on expression and variation of TGF-beta in T lymphocyte for mild persistent asthma in children
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


The effect of leukotrienes receptor antagonists on lung function, exercise tolerance and incidence of exacerbations in patients with stable, moderate COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 620s
Year: 2002

Interleukin-1R antagonist gene and pre-natal smoke exposure are associated with childhood asthma
Source: Eur Respir J 2007; 29: 502-508
Year: 2007



Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD
Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease
Year: 2010

Assessing health status in COPD
Source: Annual Congress 2013 –PG18 Assessing the health status and quality of life in asthma and COPD patients
Year: 2013


Additional overall benefit to coexistent asthma and rhinitis symptoms control in patients treated with leukotriene receptor antagonist
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Effects of tiotropium on systemic inflammation and nutrition status
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008


Influence of gender on health status response to long-term oxygen therapy in very severe COPD patients
Source: Annual Congress 2009 - Oxygen, end-of-life and care for chronic respiratory patients
Year: 2009


Predictors of health status in COPD patients
Source: Annual Congress 2008 - Basic science in asthma and COPD
Year: 2008


Effect of angiotensin II receptor antagonists on cardiovascular disorders in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 212s
Year: 2001

Salmeterol response is not affected by beta2-adrenergic receptor genotype in patients with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 505s
Year: 2005

Rates of asthma exacerbations are not affected by beta2-adrenergic receptor genotype in patients with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 708s
Year: 2005

Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 219s
Year: 2004

Effects of self-management action plans for COPD patients with comorbidities on health status and self-efficacy
Source: International Congress 2017 – Best abstracts in physical activity and management of COPD
Year: 2017

Effect of inhaled beta2 agonist on lung compliance in patients with COPD with poor bronchodilator response
Source: Eur Respir J 2006; 28: Suppl. 50, 428s
Year: 2006